Mankind Pharma has entered into an agreement with Dr Reddy’s Laboratories to acquire two of its brands Combihale and Daffy.

Combihale is used for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). The market for this category is valued at approximately Rs 900 crore growing at 14 per cent (IQVIA). The acquisition of Combihale is expected to strengthen Mankind’s presence in the inhalation respiratory market segment. Daffy is a soap-free moisturising bar for infant babies. The total market for this category is valued at approximately Rs 1,000 crores growing at 18 per cent (IQVIA), the statement further said.

"We believe these brands have adequate potential to grow in the Indian market and the best part of the acquisition is that both these brands perfectly fit in our portfolio, and provides us an opportunity to grow and build the respiratory and dermatology business further," Mankind Pharma President Atish Majumdar said.

As per the terms of the definitive agreement executed between the companies, Mankind Pharma will take over the manufacturing, marketing and distribution of both products in India. The entire integration and transition of the brands is expected to be completed by March 2022, the statement said.